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Purpose: To assess the diagnostic accuracy of magnetic resonance imaging (MRI) perfusion against perfusion single
photon emission tomography (SPECT) screening for chronic thromboembolic pulmonary hypertension (CTEPH). Ventila-
tion/perfusion (V/Q) scintigraphy is recommended to screen for suspected CTEPH. It has previously been shown that
3D dynamic contrast-enhanced (DCE) lung perfusion MRI has a similar sensitivity for diagnosing CTEPH in comparison
to planar perfusion scintigraphy; however, planar scintigraphy has now been largely replaced by SPECT, due to higher
spatial resolution and sensitivity.
Materials and Methods: Consecutive patients with suspected CTEPH or unexplained pulmonary hypertension attending
a referral center, who underwent lung DCE perfusion MRI at 1.5T, perfusion SPECT, and computed tomography pulmonary
angiography (CTPA) within 14 days of right heart catheterization, from April 2013 to April 2014, were included. DCE-MR,
SPECT, and CTPA were independently analyzed by two blinded radiologists. Disagreements were corrected by consensus.
The gold standard reference for the diagnosis of chronic thromboemboli was based on a review of multimodality imaging
and clinical findings.
Results: In all, 74 patients with suspected CTEPH underwent all three modalities. Forty-six were diagnosed with CTEPH
(36) or chronic thromboembolic disease (CTED) (10). 3D DCE perfusion MRI correctly identified all patients (sensitivity
of 100%), compared with a 97% sensitivity for SPECT.
Conclusion: DCE lung perfusion MRI has increased sensitivity when compared with perfusion scintigraphy in screening
for CTEPH. As MRI does not use ionizing radiation, it should be considered as a first-line imaging modality in suspected
CTEPH.
Level of Evidence: 3
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Chronic thromboembolic pulmonary hypertension(CTEPH) is a potentially curable form of pulmonary
hypertension (PH).1 The diagnosis requires a mean pulmo-
nary artery pressure (mPAP) 25 mmHg at right heart
catheterization (RHC), in the presence of at least one seg-
mental defect on perfusion imaging or filling defects on
computed tomography pulmonary angiography (CTPA),
after at least 3 months of effective anticoagulation.2 The
true incidence and prevalence of CTEPH is not known, but
the cumulative incidence of CTEPH after survival from an
acute pulmonary embolus is reported as 3.8% at 2 years.3
The pathological process is thought to be due to incomplete
lysis of the acute pulmonary embolus; the subsequent orga-
nization of the obstructing thrombus leading to obstruction
of pulmonary vascular bed.4 This ultimately leads to
increased pulmonary arterial pressure, right ventricular dys-
function, and if untreated the prognosis is poor.5
Patients with CTEPH usually have a history of either pul-
monary embolism or deep venous thrombosis, although a sig-
nificant proportion may present with unexplained breathlessness
or pulmonary hypertension of unknown cause.6,7 It is impor-
tant that the diagnosis of CTEPH is made, as pulmonary
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endarterectomy is associated with increased survival and a favor-
able functional outcome in CTEPH.1 The 2013 World Sym-
posium on Pulmonary Hypertension recommended single
photon emission computed tomography (SPECT) ventilation/
perfusion (V/Q) scintigraphy as the preferred screening test for
CTEPH,8 but this entails injection of 100MBq of 99mTc-
labeled macroaggregated human albumin, resulting in exposure
to ionizing radiation with an effective dose of 0.017 mSv/
MBq.9
Cardiopulmonary magnetic resonance imaging (MRI)
is emerging as an important tool for assessing the structure
and function of the right ventricle in patients with PH,10
and it has already been shown that 3D dynamic contrast-
enhanced (DCE) lung perfusion MRI has a similar sensitivity
for diagnosing CTEPH when compared with planar perfusion
scintigraphy.11 Planar scintigraphy is increasingly being replaced
by SPECT in clinical practice, due to the higher spatial resolu-
tion and improved sensitivity in the detection of smaller perfu-
sion defects.12 Thus, the aim of this study was to assess the
diagnostic accuracy of MRI perfusion against perfusion SPECT
as a screening tool for CTEPH.
Patients and Methods
Consecutive patients with suspected CTEPH or unexplained pul-
monary hypertension attending a pulmonary hypertension referral
center13 who underwent contrast-enhanced lung perfusion MRI,
perfusion SPECT, and CTPA within 14 days of right heart cathe-
terization, from April 2013 to April 2014, were identified. A diag-
nosis of CTEPH was based on a review of multimodality imaging,
clinical correlates, and right heart catheterization as per standard
clinical criteria2; this was decided at a multi-disciplinary team
meeting and was used as the reference standard. Patients with
chronic thromboembolic disease, but without pulmonary hyperten-
sion, were considered a true positive. This was decided since the
current method of diagnosis of pulmonary hypertension is not
made on imaging, but instead relies on pressure measurements in
the pulmonary artery on right heart catheterization. The local
Research Ethics Committee granted ethical approval for this retro-
spective study, and written consent was waived.
Image Acquisition
MRI was performed on a 1.5T whole body system (HDx, GE
Healthcare, Milwaukee, WI) using a time-resolved 3D spoiled gradi-
ent echo sequence with view-sharing. An 8-channel cardiac receiver
array coil was used. The sequence parameters were: TE5 1.1 msec,
TR5 2.5 msec, flip angle 308, field of view 48 3 48 cm, parallel
imaging in plane 32, in-plane resolution 200 3 80, bandwidth 250
kHz, slice thickness 10mm, 32 slices, 48 timepoints with an over-
all effective 3D frame rate of 0.5 seconds. Images were acquired in
a coronal orientation during a single breath-hold. The acquired voxel
size was 1.875 3 1.875 3 10mm. Contrast injection of a 0.05ml
per kg patient weight dose of Gd-BT-D30A (Gadovist, Schering,
Berlin, Germany) was injected at a rate of 4ml per second with the
injection rate controlled using an activated pump injector (Spectris,
MedRad, Pittsburgh, PA) typically via a vein in the antecubital fossa
using an 18G cannula, followed by a 20-ml saline flush.
SPECT imaging was performed on a GE Infinia SPECT sys-
tem using a low energy general-purpose collimator; 100MBq
99mTc MAA was administered through a direct intravenous injec-
tion with a needle of 21G or larger. The image acquisition parame-
ters were: acquisition matrix 128 3 128, 60 projections per
detector and 7 seconds per projection. Images were acquired prone
with the patient’s arms extended above their heads, where possible.
Image Analysis
DCE perfusion images were analyzed on a slice-by-slice basis by
subtraction of the baseline precontrast image; this was performed
on a GE Advantage workstation. The peak enhancement image in
the contrast passage time series was independently analyzed by a
general radiologist (C.S.J., 5 years of experience) and a consultant
chest radiologist (A.J.S., 11 years of experience) blinded to all oth-
er imaging and clinical information. The images were reviewed on
a general reporting workstation in the general radiology depart-
ment on diagnostic quality Barco screens (Barco, UK). The images
were qualitatively assessed as either positive or negative for chronic
thromboembolic disease. On both DCE perfusion MRI and perfu-
sion SPECT, the presence of one or more segmental or subsegmen-
tal perfusion defects was considered positive for pulmonary
embolic disease, as per recognized clinical guidelines.14 Figure 1
gives an example of a normal and positive SPECT and DCE-MRI
scan. The DCE perfusion images were typically viewed with a win-
dow of 40 and a level of 19, although this was manipulated if
required. Subsequently, the SPECT imaging was reviewed by the
same radiologists, at a separate sitting, separated from the time of
the MRI analysis by at least 1 week, blinded to all other imaging
and clinical information. Any disagreements were resolved by con-
sensus. The multidisciplinary decision of the presence or absence
FIGURE 1: Matched slices from 3D coronal SPECT perfusion
images (top row) and DCE MR perfusion images (bottom) in a
patient with normal lung perfusion (A) and with CTEPH (B).
This shows the typical wedge-shaped perfusion defects (arrows)
in the right mid, left lower, and left upper zones on the MR
and the SPECT imaging of patient B. Note the images are
presented on an inverse gray scale as reviewed clinically.
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of chronic thromboembolic disease, as outlined above, was consid-
ered the reference standard.
Statistical Analysis
Diagnostic accuracy was assessed for SPECT and DCE perfusion
MRI using a 232 predictive table to calculate sensitivity, specificity,
negative and positive predictive value. Interobserver and intertest
agreement was assessed using kappa, with 0.60–0.79 considered
moderate agreement, 0.80–0.89 strong, and above 0.90 excellent
agreement.15 Statistical analysis was performed using SPSS 22 (IBM,
Chicago, IL) and GraphPad Prism 7 (GraphPad Software, San
Diego, CA). P < 0.05 was considered statistically significant.
Patient Demographics
Over the 1-year period of the study, 74 patients with suspected
CTEPH attended for perfusion MRI, SPECT, and CTPA. Thirty-
six patients were diagnosed with CTEPH and 10 patients with
CTED (chronic thromboembolic disease without pulmonary
hypertension) according to standard criteria. In the CTEPH and
CTED groups there were 20 female and 26 male patients. The
mean age of both groups was 62 years (standard deviation 14 years).
Results
DCE perfusion MRI correctly identified all CTEPH and
CTED patients (sensitivity of 100%), compared to 97%
sensitivity for SPECT; P-values for all data were < 0.0001
(see Table 1 for more details). The specificity of MR was
81% and SPECT 81%. The patient not identified by
SPECT had mild, inoperable CTEPH, and was correctly
identified on CTPA and perfusion MRI. There was one
indeterminate SPECT case and two indeterminate MRI
cases. The kappa value between SPECT and MRI was 0.88,
indicating strong agreement. Interobserver kappa was 0.80
and 0.88 for SPECT and MRI, respectively, indicating
strong interobserver agreement.
Discussion
DCE lung perfusion MRI has increased sensitivity when
compared to SPECT perfusion scintigraphy in the detection
of CTEPH. In the patients studied, a combination of perfu-
sion MR and CTPA identified all patients with CTEPH
and CTED. This reflects and updates the findings of a pre-
vious study by Rajaram et al that compared DCE perfusion
MRI with planar scintigraphy.11 There were two indetermi-
nate sets of MRI scans; it was felt that low signal-to-noise
ratios in these images was the underlying reason for an inde-
terminate study. Perfusion MRI can be performed in the
same sitting as high-resolution pulmonary MR angiography
and cardiac MRI scan, and has the potential for a “one-
stop-shop” analysis of pulmonary perfusion and assessment
of right heart and pulmonary vascular characteristics. Cardiac
MR assessment of baseline and progression of right ventricular
characteristics over time in idiopathic pulmonary artery hyper-
tension (IPAH) has been previously shown to be a predictor
of outcome.16,17
These results differ somewhat from the literature regard-
ing MR in the diagnosis of acute pulmonary emboli (PE).
The PIOPED III study assessed the efficacy of MR angiogra-
phy (MRA), and showed a sensitivity of 78% for acute PE
detection in technically adequate scans; 25% of patients had
technically inadequate scans.18 Although it should be noted
that, while contrast-enhanced MRA and DCE perfusion
images are different methods for assessment of the pulmonary
vasculature, in that MRA focuses on structural form of the
major vessels while DCE perfusion MR highlights downstream
perfusion of the small vessels, it is likely that the main differ-
ence in the sensitivity of MR in the assessment of acute and
chronic PE could be due to the size of thrombus detected.
Due to improvements in technologies, modern-day CTPA is
able to pick up very small subsegmental acute PEs, which (in
our opinion), are likely to be smaller than those that can be
currently detected on MRA or MR perfusion imaging. These
peripheral acute emboli are very unlikely to cause CTEPH, so
the lower spatial resolution of MRA and perfusion imaging
when compared to CTPA should not miss clinically significant
chronic thromboembolic disease. In the present study, DCE-
MRI had the highest sensitivity for detecting CTEPH,
although SPECT Q only failed to identify a single patient
with distal thromboembolic disease. Importantly, however, no
modality missed surgically accessible CTEPH. The case that
was missed by SPECT was in a patient with coexistent lung
pathology, which caused a defect that was not typical of
embolic disease on the SPECT image; the anatomical informa-
tion available on the nonsubtracted MRI database meant that
TABLE 1. Summary of Diagnostic Performance of SPECT and MR Perfusion
SPECT perfusion Perfusion MRI
Sensitivity 97% (95% CI 88–99%) 100% (95% CI 92–100%)
Specificity 81% (95% CI 62–94%) 81% (95% CI 62–94%)
Positive predictive value 90% (95% CI 78–97%) 90% (95% CI 78–97%)
Negative predictive value 96% (95% CI 78–100%) 100% (95% CI 85–100%)
Interobserver agreement (kappa) 0.80 0.88
The P-values for all data were< 0.0001.
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was less of an issue for the MR perfusion scan. It should be
noted that CTEPH and CTED may be missed on CTPA by
radiologists not experienced in the assessment of pulmonary
vascular disease, leading to the recommendation in the latest
international guidelines that SPECT Q is preferred to CTPA
when screening for CTEPH.14 Given the similarities between
the images obtained by DCE-MRI and SPECT Q, it is antici-
pated that DCE-MRI would have similar diagnostic perfor-
mance in the hands of a general radiologist.
Although SPECT imaging and DCE perfusion MRI
both demonstrate pulmonary perfusion of the small (sub-
voxel size) vessels, there are fundamental differences in the
method of acquisition and contrast enhancement. SPECT
imaging represents deposition of radio-isotope particles in
the capillaries and small arterioles in the lung,9 with acquisi-
tion times around 10 minutes in a pseudosteady-state of
lung perfusion. DCE MR perfusion images are, however,
dynamically acquired in the first pass of gadolinium; and a
3D dataset is acquired (here, approximately every 0.5 sec)
during a breath-hold. The initial “unenhanced” prebolus
arrival dataset is subtracted from the peak enhancement
dataset to give the perfusion images. As such, the MR
images are interpreted as a snapshot of the “peak” first-pass
perfusion signal and also the enhanced signal from blood in
the conducting major vessels is not explicitly segmented
from the signals from the rest of the pulmonary blood pool.
An alternative method of analysis that might closer
represent the cumulative signal of a SPECT scan would be
to integrate the dynamic perfusion signal with time to create
maps of regional perfused blood volume.19 An example of
the quantitative parametric maps of pulmonary perfusion is
provided in Fig. 2. Using the arterial input function and
unenhanced lung T1 maps, time-contrast curves can be cal-
culated for each voxel and peak contrast, mean transit time,
and pulmonary perfusion can be calculated, as previously
described.20,21 These are calculated for each voxel over the
time-course of the perfusion dataset and can be presented in
a parametric map. Techniques to segment out the major ves-
sels could also be employed to mask the signal from the
perfused capillary bed,22 although background signal from
the major vessels was not felt to affect the radiological inter-
pretation of the images in this study.
This study has a number of limitations. As our study
was conducted in a pulmonary hypertension referral center,13
the negative and positive predictive value will only be valid
for a population where the probability of CTEPH and
CTED is high, although given the high sensitivity and specif-
icity of MRI, it would be expected to perform well in symp-
tomatic patients following PE where the prevalence of
CTEPH is increased. The retrospective nature of the study
has the potential to introduce bias; however, both reviewers
were blinded to each other’s observations and clinical infor-
mation. A prospective study examining the value of MRI and
SPECT VQ as a screening test for CTEPH will be required
to address the clinical utility and diagnostic performance of
these investigations in populations at risk.
In conclusion, MRI has high sensitivity for CTEPH
and does not use ionizing radiation making it an ideal imag-
ing screening test for patients with suspected CTEPH.
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